EXPLORATION OF HYDROXYL SUBSTITUTED REGORAFENIB DERIVATIVES AS A TYROSINE KINASE INHIBITORS OF LEUKIMIA THROUGH MOLECULAR DOCKING. FMHR 2026, 4 (3), 3863-3874.